Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC

Nivolumab, pembrolizumab or atezolizumab will be administered as per the established standard of care for the eligible population.

Analysis of drug-mediated changes in the tumor microenvironment.

Evaluation of tumor response using the set of published rules to determine if a tumor has responded, is stable or progressed during treatments.